Why Helus Pharma Inc.’s (HELP) Stock Is Down 5.54%
As of Tuesday, November 17, Helus Pharma Inc.’s HELP share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Rosalio Madrigal
Michael Rose
Tudor Pop
| Share Statistics | HELP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $495.3 | $403.8 | 39% |
|
| Shares Out (Mil) | 73.1 | 47.2 | 56% |
|
| Institutional Ownership | 68.7% | 82.0% | 42% |
|
| Float (Mil) | 56.7 | 49.0 | 49% |
|
| Beta | na | 0.68 | na |
|
| Avg Daily Volume (000s) | 2,851 | 347 | 86% |
|
| Price Change (52-week) |
12.6% | 51.1% | 64% |
|
| Growth | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.6% | na |
|
| Net Income (5yr) | (42.0%) | (1.4%) | 9% |
|
| EPS (5yr) | 15.3% | 15.1% | 58 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (40.2%) | (15.1%) | 12% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 4 | 5 | |
| Current EPS | ($0.661) | ($3.668) | ($2.411) | |
| Month Ago EPS | ($0.615) | ($2.601) | ($1.775) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.613) | ($2.589) | ($1.775) | |
| Year/Year Chg | (53.2%) | (13.7%) | (54.6%) | |
| Financials | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($241) | ($11) | 5% |
|
| EPS (TTM) | ($4.412) | ($0.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($142) | ($7) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $87 | $1 | 76% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $478 | $373 | 34% |
|
| Valuation | HELP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.03 | 2.20 | 58% |
|
| P/E | na | 21.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HELP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.5% | na |
|
| ROA | (108.3%) | (24.6%) | 5% |
|
| ROE | (125.5%) | (24.4%) | 7% |
|
| Liabilities to Assets | 7.1% | 32.0% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Helus Pharma Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors